Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow, India.
Bioorg Med Chem Lett. 2010 Aug 1;20(15):4459-63. doi: 10.1016/j.bmcl.2010.06.045. Epub 2010 Jun 12.
A new series of 6-(4'-aryloxy-phenyl)vinyl-1,2,4-trioxanes 10a-d, 11a-d, and 12a-d have been synthesized and evaluated for their antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice by oral route. Trioxanes 10b and 10c, the two most active compounds of the series, provided 100% protection to the infected mice at 48 mg/kg x 4 days. Clinically useful drug beta-arteether provided 100% and 20% protection at 48 mg/kg x 4 days and 24 mg/kg x 4 days, respectively, in this model.
已合成了一系列新的 6-(4'-芳氧基-苯基)乙烯基-1,2,4-三恶烷 10a-d、11a-d 和 12a-d,并通过口服途径在瑞士小鼠中评估了它们对耐多药恶性疟原虫的抗疟活性。三恶烷 10b 和 10c 是该系列中最有效的两种化合物,以 48mg/kg x 4 天的剂量给药时,可使感染的小鼠 100%得到保护。在该模型中,临床有用的药物青蒿琥酯以 48mg/kg x 4 天和 24mg/kg x 4 天的剂量给药时,分别提供了 100%和 20%的保护。